IDP Pharma and BCN Peptides has entered a collaboration for the development of peptidomimetics. IDP Pharma will use its technology, IDP-Platform , to design peptidomimetics with target-specificity, intrinsic cell permeability properties and enhanced stability to target intra cellular proteins. BCN Peptide will optimize the synthesis and scale up the lead compounds.

IDP Pharma and BCN Peptides engage in the development of a new chemical entity aimed to treat Multiple Myeloma. The collaborative project has been granted with funds from the European Union FEDER via ACCIO and its programme “Nuclis d’Innovació Tecnológica”.